CD274 and cancer: Cancer immunotherapy via antibody-based PD-1/PD-L1 blockade has provided a major breakthrough for the treatment of multiple advanced and metastatic cancers since the approval of the monoclonal antibodies targeting the PD-1/PD-L1 axis.